These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23131422)

  • 1. Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Halvorsen B; Ose L; Aukrust P; Holven KB
    Cytokine; 2013 Jan; 61(1):194-8. PubMed ID: 23131422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.
    El Messal M; Beaudeux JL; Drissi A; Giral P; Chater R; Bruckert E; Adlouni A; Chapman MJ
    Clin Chim Acta; 2006 Apr; 366(1-2):185-9. PubMed ID: 16280123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia.
    Narverud I; Halvorsen B; Nenseter MS; Retterstøl K; Yndestad A; Dahl TB; Ulven SM; Olstad OK; Ose L; Holven KB; Aukrust P
    J Intern Med; 2013 Jan; 273(1):69-78. PubMed ID: 22891927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects.
    Holven KB; Halvorsen B; Bjerkeli V; Damås JK; Retterstøl K; Mørkrid L; Ose L; Aukrust P; Nenseter MS
    Stroke; 2006 Jul; 37(7):1731-6. PubMed ID: 16728689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia.
    Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A
    Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family history of hypertension, anthropometric parameters and markers of early atherosclerosis in young healthy individuals.
    Solini A; Santini E; Passaro A; Madec S; Ferrannini E
    J Hum Hypertens; 2009 Dec; 23(12):801-7. PubMed ID: 19339995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
    Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
    Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein levels and not mutation status predict intima-media thickness in familial hypercholesterolemia.
    Fahed AC; Habib RH; Nemer GM; Azar ST; Andary RR; Arabi MT; Moubarak EM; Bitar FF; Haddad FF
    Ann Vasc Surg; 2014 Feb; 28(2):421-6. PubMed ID: 24120234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.